News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

9

February

2026

Clearmind Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Clinical Trial
Read More
6

February

2026

Clearmind Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic MEAI
Read More
3

February

2026

Clearmind’s Proprietary MEAI was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Treatments
Read More
14

January

2026

Clearmind Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial
Read More
31

December

2025

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
Read More
24

December

2025

Clearmind Medicine Reflects on a Transformative 2025
Read More
16

December

2025

Clearmind Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Read More
12

December

2025

Clearmind's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for AUD Treatment
Read More
10

December

2025

Clearmind Medicine Announces 1-for-40 Reverse Share Split
Read More
2

December

2025

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial
Read More
25

November

2025

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center
Read More
24

November

2025

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100
Read More
20

November

2025

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
Read More
18

November

2025

Clearmind Announces Positive Top-Line Results from 1st Cohort of FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Read More
17

November

2025

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
Read More